2023
Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat N, Mani A. Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients 2023, 15: 2323. PMID: 37242206, PMCID: PMC10222271, DOI: 10.3390/nu15102323.Peer-Reviewed Original ResearchConceptsFatty liver diseaseLiver diseaseHepatocellular carcinomaAlcoholic fatty liver diseaseNonalcoholic fatty liver diseaseInsulin-resistant liverDiet-induced steatosisCurrent therapeutic effortsDysregulation of lipidAccumulation of lipidsHepatic fatPrevalent conditionSevere stagesGenetic predispositionGlucose metabolismHealthcare costsEconomic burdenTherapeutic effortsDiseaseNAFLDCanonical insulinSteatosisLiverCirrhosisSteatohepatitis
2022
Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice
Bhat N, Narayanan A, Fathzadeh M, Kahn M, Zhang D, Goedeke L, Neogi A, Cardone RL, Kibbey RG, Fernandez-Hernando C, Ginsberg HN, Jain D, Shulman G, Mani A. Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. Journal Of Clinical Investigation 2022, 132: e153724. PMID: 34855620, PMCID: PMC8803348, DOI: 10.1172/jci153724.Peer-Reviewed Original ResearchConceptsDe novo lipogenesisNonalcoholic steatohepatitisInsulin resistanceHepatic lipogenesisElevated de novo lipogenesisNonalcoholic fatty liver diseaseFatty liver diseaseLiver of patientsHepatic glycogen storageHigh-sucrose dietHepatic insulin resistanceFatty acid uptakeMetabolic syndromeLiver diseaseHepatic steatosisTriacylglycerol secretionNovo lipogenesisHepatic insulinTherapeutic targetImpaired activationAcid uptakeGlycogen storageMouse liverLiverLipogenesis